American Peptide Company expands its manufacturing and service portfolio
In a slow economy, pharmaceutical and biotech companies facing increasing pressure to reduce costs, risk, and time-to-market, and maximize efficiencies have converged on a sound business strategy: outsource non-core functions such as peptide manufacturing. To help meet rising outsourcing demands and the life sciences industry’s quality concerns, American Peptide Company has ramped up its cGMP (current Good Manufacturing Practice) peptide manufacturing capabilities as well as its service offerings. As a result, the company can rapidly provide viable peptide-based solutions to speed time-to-market while maintaining stringent production standards.
The company’s significant expansion of its Vista, California facility allows it to process large-scale innovative peptide production needs while still meeting the high standards of GMP regulations. The facility expansion includes three main areas: purification, synthesis and lyophilization. Four new peptide purification suites have been added for large scale purification projects. Construction of two new synthesis suites, both for solution phase and solid phase will be planned. Finally for the lyophilization process, another capacity tray will be added to enable release of multi-Kg single batches of peptide APIs.
“As the demand for peptide-based therapies increases, we are constantly seeking ways to enhance our operations to better meet customer demands for large volumes without compromising our high standards for production.” said Takahiro Ogata, president and COO, American Peptide Company.
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
